#ESCCongress – [Abstract Only] Randomized Trial: No Overall Benefit from Ticagrelor added to Aspirin in Patients with Stable Coronary Disease and Diabetes

Ticagrelor in Patients with Stable Coronary Disease and Diabetes – New England Journal of Medicine (link to abstract – $ for full-text)

Related Study: Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial – The Lancet (free registration required)

Commentaries: THEMIS: No overall benefit of ticagrelor in people with diabetes, coronary artery disease – Medicine Matters (free) AND THEMIS, THEMIS-PCI Assess Benefits of Ticagrelor Plus Aspirin in Patients With Stable CAD and Diabetes, History of PCI – American College of Cardiology (free)

Related Commentary on Twitter

THEMIS: Among patients with stable IHD & type 2 diabetes, ticagrelor+aspirin➡⬇️risk of major adverse ischemic events, but with an ⬆ in major bleeding events compared with the placebo/aspirin group.@escardio #ACC #ESCCongress @DLBHATTMD @iamritu @ErinMichos @AnastasiaSMihai pic.twitter.com/aAeLDEiVsY

— Meghana Prakash (@megnahprakash) September 1, 2019